If you have been reading about 肽类药物 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Appearance | Lyophilized powder | White to off-white solid |
| Storage temperature | Approximately -20 °C | Dry, dark, desiccated |
| Solubility | Water-soluble peptide | Depends on sequence and buffer |
| Identity method | Mass spectrometry | Confirms expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main-peak proportion |
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
He has published extensively on historical demography, focusing especially on long-run changes in multi-generational families, single parenthood, divorce, and marriage, and data and methods for population history. His study of the effects of demographic change on family structure won the William J. Goode Book Award from the American Sociological Association and the Allen Sharlin Memorial Award from the Social Science History Association. Ruggles's work on migration censoring in family reconstitution stimulated a debate about biases introduced by the "Ruggles Effect." Ruggles was also a prominent contributor to the debate about disclosure control in the 2020 U.S. Census. Ruggles received a 2003 Robert J. Lapham Award from the Population Association of America in recognition of lifetime contributions that blend research with the application of demographic knowledge to policy issues, and in 2009 he received the Warren E. Miller Award from the Inter-university Consortium for Political and Social Research for meritorious service to the social sciences. In 1995, Ruggles was described as the "King of Quant" by Wired Magazine, and in 2014, he was named “Wonkblog-Certified Data Wizard” by the Washington Post Wonkblog, which noted that "losing to Steven Ruggles in Name That Data is kind of like losing to Adele on American Idol." In 1994, Ruggles married Lisa Norling, another historian. They have two daughters.
In the above reaction (where the dash represents a bond, not a minus sign), X would be the donor, and Y would be the acceptor. R denotes the functional group transferred as a result of transferase activity. The donor is often a coenzyme.
As can be seen, trypsinogen activation to trypsin is essential, because it activates its own reaction, as well as the reaction of both chymotrypsin and elastase. Therefore, it is essential that this activation does not occur prematurely. There are several protective measures taken by the organism to prevent self-digestion:
While slavery had technically been banned by colonial France in French West Africa (including Mauritania) already in 1905, this had been a purely nominal ban. The 1981 ban on slavery was not enforced in practice, as legal mechanisms to prosecute those who used slaves were not implemented until 2007.
Sources: en.wikipedia.org
=== History === Calendula was not a major medicinal herb but it was used in historic times for headaches, red eye, fever and toothaches. As late as the 17th century Nicholas Culpeper claimed Calendula benefited the heart, but it was not considered an especially efficacious medicine. In historic times Calendula was more often used for magical purposes than medicinal ones. One 16th-century potion containing Calendula claimed to reveal fairies. An unmarried woman with two suitors would take a blend of powdered Calendula, marjoram, wormwood and thyme simmered in honey and white wine used as an ointment in a ritual to reveal her true match. Ancient Romans and Greeks used the golden Calendula in many rituals and ceremonies, sometimes wearing crowns or garlands made from the flowers. One of its nicknames is "Mary's Gold", referring to the flowers' use in early Christian events in some countries. Calendula flowers are sacred flowers in India and have been used to decorate the statues of Hindu deities since early times. The most common use in historic times was culinary, however, and the plant was used for both its color and its flavor. They were used for dumplings, wine, oatmeal and puddings. In English cuisine Calendula were often cooked in the same pot with spinach, or used to flavor stewed birds. According to sixteenth-century Englishman John Gerard, every proper soup of Dutch cuisine in his era would include Calendula petals.
== Structure == Retinal dehydrogenase is a tetramer of identical units, consisting of a dimer of dimers. Retinal dehydrogenase monomers are composed of three domains: a nucleotide-binding domain, a tetramerization domain, and a catalytic domain. The dimer can be pictured as an "X" with the dimers forming upper and lower halves that cross over each other. Interestingly, the nucleotide-binding domain of retinal dehydrogenase contains 5 instead of the usual 6 β-strands in the Rossman fold. This appears to be conserved across many aldehyde dehydrogenases. The tetramerization domains lie equatorially along the "X" and the nucleotide binding regions appear on the tips of the "X". Nearby the tetramerization domain lies a 12 Å deep tunnel that gives the substrate access to the key catalytic regions. Residues near the C-terminal end of the catalytic domain have been found to impart specificity in other aldehyde dehydrogenases. Common to many aldehyde dehydrogenases is a catalytic cysteine, which was found to be present in ALDH1A2 (aka RALDH2), one of the retinal dehydrogenase for which the structure has been solved.
The ELP can be conjugated to a functional group that can bind to a protein of interest. At temperatures below the Tt, the ELP will bind to the ligand in its linear form. In this linear state, the ELP-protein complex cannot easily be distinguished from the extraneous proteins in the solution. However, once the solution is heated to a temperature exceeding the Tt, the ELP will form spherical clumps. These clumps will then settle to the bottom of the solution tube following centrifugation, carrying the protein of interest. The proteins that are not needed will be found in the supernatant, which can be physically separated from the spherical aggregates. To ensure that there are few impurities in the ELP-protein complex isolated, the solution can be cooled below the Tt, enabling the ELPs to once again assume their linear structure. From this point, hot and cold centrifugation cycles can be repeated, and then the protein of interest can be eluted from the ELPs via the addition of a salt.
Sources: en.wikipedia.org
Recently, a second parallel enzyme-dependent protective pathway was independently discovered by two labs that involves the oxidoreductase FSP1 (also known as AIFM2). FSP1 enzymatically reduces non-mitochondrial coenzyme Q10 (CoQ10), thereby generating a potent lipophilic antioxidant that suppresses the propagation of lipid peroxides. Vitamin K is also reduced by FSP1 to a hydroquinone species that also acts as a radical-trapping antioxidant and suppressor of ferroptosis. A similar mechanism for a cofactor moonlighting as a diffusable antioxidant was discovered in the same year for tetrahydrobiopterin (BH4), a product of the rate-limiting enzyme GTP cyclohydrolase 1 (GCH1). Hydropersulfides have been found to inhibit ferroptosis by acting as endogenous radical-trapping antioxidants.
== Pharmacology == The topical application of monobenzone in animals increases the excretion of melanin from melanocytes. The same action is thought to be responsible for the depigmenting effect of the drug in humans. Monobenzone may cause destruction of melanocytes and permanent depigmentation. The histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo; the epidermis is normal except for the absence of identifiable melanocytes. Therefore, monobenzone is used as a topical medicine to permanently depigment normal skin surrounding vitiliginous lesions only in patients with disseminated (greater than 50 percent of body surface area) idiopathic vitiligo. Monobenzone is also being considered for the treatment of melanoma.
Although it has expanded outward from its original geographic base, most new restaurants are located in suburban areas of the Southern US. Since 1997, the Atlanta-based company has sponsored the Peach Bowl, an annual college football bowl game played in Atlanta on New Year's Eve. Chick-fil-A also sponsors the Southeastern Conference and the Atlantic Coast Conference of college athletics. In 2008, Chick-fil-A was among the first fast-food restaurants to become completely free of trans fats. In October 2015, the company opened its largest restaurant, a three-story 5,000 square feet (460 m2) restaurant in Manhattan.
Sources: en.wikipedia.org
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.
Lower temperatures slow chemical degradation reactions such as hydrolysis and oxidation. Light and moisture protection addresses additional pathways that can alter the molecule during storage.
A purity figure describes the proportion of the detected signal attributed to the main peak under a specific method. Different methods can produce different values for the same sample.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.